Cargando…
Health Canada's Proposal to Accelerate New Drug Reviews
Health Canada is proposing to update its accelerated review pathways to get important new drugs into the market more quickly. To date, the two pathways that Health Canada uses have not demonstrated that they can identify therapeutically valuable new drugs. Drugs approved under the two pathways also...
Autor principal: | Lexchin, Joel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Longwoods Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294445/ https://www.ncbi.nlm.nih.gov/pubmed/32538346 http://dx.doi.org/10.12927/hcpol.2020.26227 |
Ejemplares similares
-
Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study
por: Lexchin, Joel
Publicado: (2019) -
A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada
por: Morgan, Steven G., et al.
Publicado: (2016) -
Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
por: Lee, Shoo K., et al.
Publicado: (2023) -
The Pharmaceutical Industry and the Canadian Government: Folie à Deux
por: Lexchin, Joel
Publicado: (2017) -
Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care between Patients and Providers
por: GorFinkel, Iris, et al.
Publicado: (2019)